Quarterly ResultJun 29, 2026, 12:16 PM
MiniMed FY2026 Revenue $3.1B, Net Loss $317M
AI Summary
MiniMed Group reported fiscal year 2026 revenue of $3.1 billion, an increase from $2.7 billion in fiscal year 2025. However, the company's net loss widened to $317 million in FY2026 from $198 million in FY2025, and Adjusted EBITDA decreased to $202 million. The company continues to expand its diabetes management solutions, launching new CGM sensors and insulin pumps, and advancing its next-generation dosing algorithms, while also highlighting significant market growth potential.
Key Highlights
- FY2026 revenue reached $3.1 billion, up from $2.7 billion in FY2025.
- Net loss widened to $317 million in FY2026 from $198 million in FY2025.
- Adjusted EBITDA decreased to $202 million in FY2026 from $253 million in FY2025.
- OUS revenue comprised 70% of total revenue in FY2026 and 67% in FY2025.
- Launched MiniMed Flex insulin pump in US in June 2026 after FDA clearance.
- Plans US FDA submission for MiniMed Fit patch pump by fall 2026.
- Diabetes technology market estimated over $19 billion, growing >10% CAGR.
Price Impact
More from MMED